What to know about the new GLP-1 pills now on sale
Novo Nordisk's Wegovy and Lilly's Foundayo, oral GLP-1 weight loss pills, are now available in Australia. Experts anticipate increased demand but caution about long-term effects and misuse. Prices range from $250 to $395 monthly, comparable to injectable versions. Availability varies by pharmacy.
How this was made
The 30-second read
Why it matters
The approvals create a new revenue stream for both companies and could shift market dynamics toward oral obesity treatments.
Market read
Regulatory approval of oral GLP‑1 drugs expands market opportunities for Novo Nordisk and Eli Lilly, potentially boosting their stock performance and influencing the broader weight‑loss drug sector.
What to watch
Australian reimbursement policies and consumer price sensitivity may affect uptake.
Background
Australia approved the first oral GLP‑1 pills for weight loss, with Novo Nordisk's Wegovy and Eli Lilly's Foundayo entering pharmacies. Experts note potential demand surge but raise concerns about long‑term safety and pricing.
Ticker impact
Novo Nordisk received TGA approval for its oral Wegovy GLP-1 pill, launching in Australian pharmacies this Friday.
likely upside as investors price in additional revenue from oral GLP-1 sales
First approval of an oral GLP-1 expands market reach and adds revenue potential, prompting positive market reaction.
Eli Lilly announced its oral GLP-1 pill Foundayo will be available in Australia after TGA approval, entering the market in the coming days.
potential upside as the market anticipates new revenue from Australian sales
Entry into the Australian oral GLP-1 market adds growth opportunity, likely supporting the stock.
Market effects
Weight‑loss drug sector may see increased demand for oral GLP‑1 therapies.
Australian pharma market gains a new oral obesity treatment, potentially boosting local sales.
Global GLP‑1 market could grow as oral options expand, influencing US‑listed pharma stocks.
Counterpoint
Overprescription risks and high pricing could limit adoption and dampen sales expectations.
Key entities
- CompanyNovo Nordisk
Pharmaceutical company launching oral Wegovy GLP‑1 pill in Australia.
- CompanyEli Lilly
Pharmaceutical company launching oral Foundayo GLP‑1 pill in Australia.
- RegulatorTherapeutic Goods Administration (TGA)
Australian regulator that approved the oral GLP‑1 medications.





